Searchable abstracts of presentations at key conferences in endocrinology

ea0015p87 | Clinical practice/governance and case reports | SFEBES2008

Sarcoidosis associated hypercalcaemia and renal failure mimicking lymphoma

Bdiri Ashref , Smith Martin , Lawrence James

We describe two cases of sarcoidosis associated hypercalcaemia, renal failure and anaemia mimicking lymphoma. The diagnosis was made by lymph node biopsy. Within weeks of starting oral steroids, symptoms resolved and biochemical abnormalities almost normalized.Case 1: A 66-year-old lady, presented with generalized weakness, lymphadenopathy and splenomegaly. Hb 96 g/l, MCV 91, urea 16.6 mmol/l, creatinine 227 umol/l, eGFR 15 ml/min, serum calcium 3.4 mmol...

ea0015p343 | Thyroid | SFEBES2008

Successful discontinuation of treatment after 16 years of replacement therapy with thyroxine in congenital hypothyroidism

Talapatra Indrajit , Scott Ian , Tymms David James

We describe below a 16-year-old male referred with neonatal hypothyroidism. He was commenced on levothyroxine at the age of 3 weeks. The TSH was >100 IU/l (normal: 0.27–4.7) and Total T4 was <10 nmol/l (normal: 60–150) and there was no uptake on thyroid isotope scanning. He was diagnosed as having congenital absence of thyroid tissue and given levothyroxine and the dose adjusted to maintain normal thyroid function. His mother was diagnosed with hypothyroidism...

ea0013p15 | Bone | SFEBES2007

Hypercalcaemia from vitamin D supplements and parathyroid autonomy: the hazards of DIY therapeutics

Ahlquist James , Cranfield Lesley , Corns Cathryn

Vitamin D toxicity is a recognised consequence of vitamin D therapy arising from prescription of pharmacological doses of vitamin D; biochemical monitoring is recommended for these patients. In contrast, patients taking low-dose calcium and vitamin D (Ca+D) supplements, commonly used to reduce the risk of osteoporosis, are not regarded as at risk of vitamin D toxicity, and biochemical monitoring is not routine. We report a patient taking Ca+D supplements who developed hypercal...

ea0013p192 | Diabetes, metabolism and cardiovascular | SFEBES2007

Use of Octreotide in the dumping syndrome – Diabetes mellitus or disordered insulin secretion – a diagnostic dilemma?

Bhattacharya Beas , Advani Andrew , James Andy

Fasting blood glucose is key to diagnosing diabetes, whilst the Oral Glucose Tolerance Test (OGTT) is a valuable adjunct when diagnosis is borderline or inconclusive. The OGTT is often used to detect early changes in glucose tolerance and predict a likely path to overt Diabetes Mellitus for example in gestational diabetes.A 42 year old female, referred to the Endocrine services for episodes of symptomatic hypoglycaemia. Past medical history included pylo...

ea0012p53 | Diabetes, metabolism and cardiovascular | SFE2006

Proglucagon processing can be altered to produce GLP-1 in pancreatic alpha cells

James NM , Pritchard LE , Brennand JC , White A

The proglucagon-derived hormone, glucagon-like peptide–1 (GLP-1), augments both beta cell function and mass. However, GLP-1 is rapidly degraded in plasma, thereby limiting its potential as a treatment for diabetes. One approach to circumvent this problem would be to stimulate synthesis of GLP-1 locally in the islet.Emerging evidence suggests that pancreatic alpha cells, which normally produce glucagon, can adapt to produce GLP-1. This phenomenon may...

ea0011p79 | Clinical case reports | ECE2006

Ophthalmic presentations of Cushing’s syndrome

Ibrahim IM , Al-Bermani A , James RA

Introduction: Central Serous Retinopathy (CSR) is a condition characterized by the accumulation of sub-retinal fluid at the posterior pole of the fundus, creating a circumscribed area of serous retinal detachment. It is associated with increased levels of endogenous or exogenous glucocorticoids and has been described in patients with Cushing’s syndrome (CS).Here we report on two cases we recently managed in our unit, with central serous retinopathy ...

ea0007p251 | Clinical case reports | BES2004

Adrenal insufficiency as the second clinical manifestation of the primary antiphospholipid antibody syndrome

Abouglila K , James A , Stevenson M , Hanley J

Antiphospholipid antibody syndrome is characterised by recurrent venous or arterial thrombosis, thrompocytopenia and/or recurrent fetal loss in the presence of antiphospholipid antibodies. Antiphospholipid antibody syndrome may be seen in-patients with established Systemic Lupus Erythematosus or alternatively as isolated disease in-patients with no evidence of a lupus type abnormality. Antiphospholipid antibodies have been also associated with a variety of neurological and car...

ea0003p138 | Endocrine Tumours and Neoplasia | BES2002

Chronic lymphoedema improved by the diagnosis and treatment of underlying acromegaly

Sibal L , Harris M , James R

The insidious onset of symptoms and slow progression of acromegaly often results in a delay in diagnosis for several years. We report an unusual case who presented with progressive lymphoedema of the lower limbs 25 years before the diagnosis of acromegaly became apparent.A 51 year old lady presented to the surgical outpatient clinic with a twenty four year history of bilateral leg swelling and hypertension of 21 years duration. There was no antecedent h...

ea0073aep491 | Pituitary and Neuroendocrinology | ECE2021

The role of cannulated prolactin test in females of reproductive age presenting with isolated mild persistent hyperprolactinaemia on random sampling

Gad Hady , Mamoojee Yaasir , James Andy

IntroductionCurrent guidelines recommend a single elevated prolactin measurement drawn without excessive venepuncture stress as sufficient for diagnosing hyperprolactinaemia. However, previous studies have demonstrated that the cannulated prolactin test is more reliable at eliminating stress-induced hyperprolactinaemia, thus avoiding unnecessary additional investigations. We routinely perform morning serial prolactin sampling immediately after brachial v...

ea0073aep523 | Pituitary and Neuroendocrinology | ECE2021

Biliary ultrasound surveillance in patients with acromegaly treated with somatostatin receptor ligands: A large tertiary centre experience

Panagiotou Grigorios , Mamoojee Yaasir , James Andy

BackgroundSomatostatin receptor ligands (SRL) are commonly used in patients with acromegaly to control insulin growth factor 1 (IGF1) concentrations. Biliary sludge or gallstone formation are well-recognised biliary adverse events (BAE) from SRL therapy. Our current practice is to routinely monitor patients with acromegaly on SRL with ultrasound scanning (USS). Once BAE are detected, ursodeoxycholic acid (UDCA) therapy is initiated.<p class="abstext"...